Table 2 Outcome measures by psychotropic exposure

Outcomes	Adjusted for study design*		Adjusted for study design and covariates**			
	Estimated Means		Estimated Means		Absolute Difference	Estimated Effect
	Psychotropic	No Psychotropic	Psychotropic	No Psychotropic		
Length of Stay (days)[a]	12.1 (10.9, 13.3)	10.3 (9.5, 11.0)	12.1 (11.0, 13.3)	10.5 (9.8, 11.2)	1.6 (0.6, 2.7)	0.87 (0.79, 0.95)
Percent who received pharmacologic therapy[b]	39.4 (31.4, 47.3)	33.1 (28.3, 38.0)	39.3 (31.7, 46.9)	33.7 (29.2, 38.3)	5.5 (0.1, 11.0)	0.86 (0.75, 0.99)
Length of treatment (days)[a]	16.7 (13.7, 19.7)	14.3 (12.2, 16.5)	16.8 (13.8, 19.8)	14.6 (12.5, 16.8)	2.2 (-0.8, 4.5)	0.87 (0.76, 1.00)

* The adjusted analysis was performed without demographic covariates, but still accounted for the study design (i.e., fixed period/time effect and random site effect, intervention arms), randomization scheme stratification indicator (proportion of infants with NOWS treated pharmacologically at each site: lowest 3rd, middle 3rd, highest 3rd)

** The adjusted analysis accounts for the trial design (i.e. a fixed effect for the trial period, intervention group, and random site effect), randomization stratification indicator as fixed effect and adjusted by MOUD, sex, birth weight, gestational age, breastmilk feeding during hospital stay, and other substance exposures

[a] Reported as incidence rate ratio (IRR) based on a generalized linear mixed model (GLMM) with negative binomial distribution and log link function

[b] Reported as relative risk (RR) based on mixed effect Poisson regression model with robust error variance